Compile Data Set for Download or QSAR
Report error Found 189 Enz. Inhib. hit(s) with all data for entry = 13027
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752885(US20250197425, Example 61)
Affinity DataIC50: 5nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752838(US20250197425, Example 14)
Affinity DataIC50: 6nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752841(US20250197425, Example 17)
Affinity DataIC50: 9nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752830(US20250197425, Example 6)
Affinity DataIC50: 9nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752851(US20250197425, Example 27)
Affinity DataIC50: 11nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752867(US20250197425, Example 43)
Affinity DataIC50: 11nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM106950(US8592581, 1 | US20250197425, Comparative A2)
Affinity DataIC50: 11nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752881(US20250197425, Example 57)
Affinity DataIC50: 11nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752858(US20250197425, Example 34)
Affinity DataIC50: 12nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752831(US20250197425, Example 7)
Affinity DataIC50: 13nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752873((S)-3-((9-ethyl-2-(((2R*,3S*)-4,4,4-trifluoro-3-hy...)
Affinity DataIC50: 13nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752844(US20250197425, Example 20)
Affinity DataIC50: 13nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752837(US20250197425, Example 13)
Affinity DataIC50: 13nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752884(US20250197425, Example 60)
Affinity DataIC50: 14nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752879(US20250197425, Example 55)
Affinity DataIC50: 17nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752825(US20250197425, Example 1)
Affinity DataIC50: 17nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752882(US20250197425, Example 58)
Affinity DataIC50: 17nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752829(US20250197425, Example 5)
Affinity DataIC50: 18nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752827(US20250197425, Example 3)
Affinity DataIC50: 18nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752865(US20250197425, Example 41)
Affinity DataIC50: 19nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752886(US20250197425, Example 62)
Affinity DataIC50: 19nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752854(US20250197425, Example 30)
Affinity DataIC50: 19nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752842(US20250197425, Example 18)
Affinity DataIC50: 19nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752852(US20250197425, Example 28)
Affinity DataIC50: 20nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752828(US20250197425, Example 4)
Affinity DataIC50: 20nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752862(US20250197425, Example 38)
Affinity DataIC50: 21nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752876(US20250197425, Example 52)
Affinity DataIC50: 21nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752839(US20250197425, Example 15)
Affinity DataIC50: 22nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752864(US20250197425, Example 40)
Affinity DataIC50: 24nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752868(US20250197425, Example 44)
Affinity DataIC50: 26nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752857(US20250197425, Example 33)
Affinity DataIC50: 26nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752866(US20250197425, Example 42)
Affinity DataIC50: 27nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752843(US20250197425, Example 19)
Affinity DataIC50: 27nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752826(US20250197425, Example 2)
Affinity DataIC50: 29nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752875(US20250197425, Example 51)
Affinity DataIC50: 32nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752863(US20250197425, Example 39)
Affinity DataIC50: 33nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752871(US20250197425, Example 47)
Affinity DataIC50: 35nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752883(US20250197425, Example 59)
Affinity DataIC50: 37nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752848(US20250197425, Example 24)
Affinity DataIC50: 38nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752850(US20250197425, Example 26)
Affinity DataIC50: 39nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752855(US20250197425, Example 31)
Affinity DataIC50: 39nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752869(US20250197425, Example 45)
Affinity DataIC50: 39nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752877(US20250197425, Example 53)
Affinity DataIC50: 43nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752846(US20250197425, Example 22)
Affinity DataIC50: 47nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752845(US20250197425, Example 21)
Affinity DataIC50: 49nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752860(US20250197425, Example 36)
Affinity DataIC50: 50nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752859(US20250197425, Example 35)
Affinity DataIC50: 52nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752847(US20250197425, Example 23)
Affinity DataIC50: 57nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752861(US20250197425, Example 37)
Affinity DataIC50: 61nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-D1(Human)
Astrazeneca

US Patent
LigandPNGBDBM752874((S)-3-((9-ethyl-2-(((2R*,3S*)-4,4,4-trifluoro-3-hy...)
Affinity DataIC50: 64nMAssay Description:Compounds were tested in breast cancer cell line MCF-7 to assess inhibition of CDK1, CDK2, and CDK4 activity. MCF-7 cells transiently transfected wit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/15/2025
Entry Details
US Patent

Displayed 1 to 50 (of 189 total ) | Next | Last >>
Jump to: